- Home
- HG vs CLDX Comparison
HG vs CLDX Comparison
Compare HG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- CLDX
- Stock Information
- Founded
- HG 2013
- CLDX 1983
- Country
- HG Bermuda
- CLDX United States
- Employees
- HG N/A
- CLDX N/A
- Industry
- HG
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HG
- CLDX Health Care
- Exchange
- HG Nasdaq
- CLDX Nasdaq
- Market Cap
- HG 1.9B
- CLDX 1.6B
- IPO Year
- HG 2023
- CLDX 2008
- Fundamental
- Price
- HG $19.37
- CLDX $23.78
- Analyst Decision
- HG Buy
- CLDX Buy
- Analyst Count
- HG 7
- CLDX 7
- Target Price
- HG $21.71
- CLDX $64.83
- AVG Volume (30 Days)
- HG 436.0K
- CLDX 1.1M
- Earning Date
- HG 02-26-2025
- CLDX 02-24-2025
- Dividend Yield
- HG N/A
- CLDX N/A
- EPS Growth
- HG 537.51
- CLDX N/A
- EPS
- HG 4.48
- CLDX N/A
- Revenue
- HG $2,266,708,000.00
- CLDX $9,976,000.00
- Revenue This Year
- HG N/A
- CLDX N/A
- Revenue Next Year
- HG $8.12
- CLDX N/A
- P/E Ratio
- HG $4.32
- CLDX N/A
- Revenue Growth
- HG 68.94
- CLDX 128.55
- 52 Week Low
- HG $12.44
- CLDX $22.17
- 52 Week High
- HG $20.71
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- HG 59.09
- CLDX 41.99
- Support Level
- HG $18.11
- CLDX $22.17
- Resistance Level
- HG $19.02
- CLDX $29.05
- Average True Range (ATR)
- HG 0.46
- CLDX 1.57
- MACD
- HG 0.05
- CLDX -0.26
- Stochastic Oscillator
- HG 81.95
- CLDX 23.40
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in Lloyd's, Ireland, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.